

Anna MarÃ-a Cattelan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8554974/publications.pdf>

Version: 2024-02-01

103
papers

2,320
citations

236612

25
h-index

264894

42
g-index

108
all docs

108
docs citations

108
times ranked

3412
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperglycemia, Reduced Hematopoietic Stem Cells, and Outcome of COVID-19. <i>Diabetes</i> , 2022, 71, 788-794.	0.3	8
2	Brief communication: Chest radiography score in young COVID-19 patients: Does one size fit all?. <i>PLoS ONE</i> , 2022, 17, e0264172.	1.1	2
3	Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. <i>Viruses</i> , 2022, 14, 493.	1.5	17
4	Rapid Antigen Test LumiraDxTM vs. Real Time Polymerase Chain Reaction for the Diagnosis of SARS-CoV-2 Infection: A Retrospective Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3826.	1.2	7
5	Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. <i>European Journal of Internal Medicine</i> , 2022, 97, 42-49.	1.0	12
6	COVID-19 Vaccination Limits Systemic Danger Signals in SARS-CoV-2 Infected Patients. <i>Viruses</i> , 2022, 14, 565.	1.5	2
7	Small Fibre Peripheral Alterations Following COVID-19 Detected by Corneal Confocal Microscopy. <i>Journal of Personalized Medicine</i> , 2022, 12, 563.	1.1	7
8	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 443-456.	2.0	3
9	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0247275.	1.1	7
10	Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. <i>Aids</i> , 2021, 35, 939-945.	1.0	19
11	Prolonged SARS-CoV-2-RNA Detection from Nasopharyngeal Swabs in an Oncologic Patient: What Impact on Cancer Treatment?. <i>Current Oncology</i> , 2021, 28, 847-852.	0.9	3
12	Machine learning-based analysis of alveolar and vascular injury in SARS-CoV-2 acute respiratory failure. <i>Journal of Pathology</i> , 2021, 254, 173-184.	2.1	28
13	Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1288.	1.0	10
14	Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources. <i>Cancers</i> , 2021, 13, 1416.	1.7	8
15	Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. <i>European Journal of Cancer</i> , 2021, 147, 120-127.	1.3	15
16	HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection. <i>Scientific Reports</i> , 2021, 11, 9274.	1.6	0
17	Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens. <i>Pathology Research and Practice</i> , 2021, 221, 153451.	1.0	30
18	Lower Gene Expression of Angiotensin Converting Enzyme 2 Receptor in Lung Tissues of Smokers With COVID-19Pneumonia. <i>Biomolecules</i> , 2021, 11, 796.	1.8	2

#	ARTICLE	IF	CITATIONS
19	Reduced muscle mass as predictor of intensive care unit hospitalization in COVID-19 patients. PLoS ONE, 2021, 16, e0253433.	1.1	30
20	Disease Severity and Prognosis of SARS-CoV-2 Infection in Hospitalized Patients Is Not Associated With Viral Load in Nasopharyngeal Swab. Frontiers in Medicine, 2021, 8, 714221.	1.2	9
21	Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection. Clinical Chemistry and Laboratory Medicine, 2021, 59, 775-782.	1.4	12
22	Durability of Integrase STRand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPP0 cohort. PLoS ONE, 2021, 16, e0258533.	1.1	0
23	IL1 β Promotes TMPRSS2 Expression and SARS-CoV-2 Cell Entry Through the p38 MAPK-GATA2 Axis. Frontiers in Immunology, 2021, 12, 781352.	2.2	18
24	Characteristics and Prognostic Factors of Pulmonary Fibrosis After COVID-19 Pneumonia. Frontiers in Medicine, 2021, 8, 823600.	1.2	20
25	Antibiotic therapy for spontaneous bacterial peritonitis in acute-on-chronic liver failure: Handle with care. Digestive and Liver Disease, 2020, 52, 116-117.	0.4	1
26	Retrospective Analysis of a Modified Organizational Model to Guarantee CT Workflow during the COVID-19 Outbreak in the Tertiary Hospital of Padova, Italy. Journal of Clinical Medicine, 2020, 9, 3042.	1.0	4
27	An Integrated Strategy for the Prevention of SARS-CoV-2 Infection in Healthcare Workers: A Prospective Observational Study. International Journal of Environmental Research and Public Health, 2020, 17, 5785.	1.2	26
28	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093458.	1.4	7
29	Clinical Features and Chest Imaging as Predictors of Intensity of Care in Patients with COVID-19. Journal of Clinical Medicine, 2020, 9, 2990.	1.0	20
30	Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study. BMC Infectious Diseases, 2020, 20, 934.	1.3	25
31	Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients. Cell Death and Disease, 2020, 11, 957.	2.7	88
32	Clinical Features and Mortality of Nosocomial Candidemia in Very Old Patients: A Multicentre Italian Study. Gerontology, 2020, 66, 532-541.	1.4	8
33	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. Antibiotics, 2020, 9, 71.	1.5	68
34	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infectious Diseases, 2020, 7, ofaa139.	0.4	49
35	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. Patient, 2020, 13, 375-387.	1.1	5
36	SARS-CoV-2 and hepatitis. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 473-475.	0.5	15

#	ARTICLE	IF	CITATIONS
37	Invasive fungal infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 7485-7496.	1.4	26
38	Circulating miRNA-375 as a potential novel biomarker for active Kaposi's sarcoma in AIDS patients. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1486-1494.	1.6	8
39	Cochlear-Vestibular Impairment due to West Nile Virus Infection. <i>Annals of Otology, Rhinology and Laryngology</i> , 2019, 128, 1198-1202.	0.6	6
40	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPP" Cohort. <i>PLoS ONE</i> , 2019, 14, e0222225.	1.1	9
41	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study). <i>PLoS ONE</i> , 2019, 14, e0222650.	1.1	11
42	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNa cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	1.2	46
43	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1187-1197.	1.3	5
44	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , 2019, 33, 1256-1260.	1.0	10
45	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	6.3	265
46	Ceftolozane/tazobactam for the treatment of serious <i>Pseudomonas aeruginosa</i> infections: a multicentre nationwide clinical experience. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 408-415.	1.1	120
47	Reply to Fontaine. <i>Clinical Infectious Diseases</i> , 2018, 67, 1144-1145.	2.9	2
48	Virus and Antibody Dynamics in Travelers With Acute Zika Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 1173-1180.	2.9	98
49	Cyclophosphamide immunomodulation of TB-associated cerebral vasculitis. <i>Infectious Diseases</i> , 2018, 50, 779-782.	1.4	5
50	Soluble CD163 and soluble CD14 plasma levels but not cellular HIV-DNA decrease during successful interferon-free anti-HCV therapy in HIV-1/HCV co-infected patients on effective combined anti-HIV treatment. <i>Medical Microbiology and Immunology</i> , 2018, 207, 183-194.	2.6	20
51	Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. <i>HIV Clinical Trials</i> , 2018, 19, 242-248.	2.0	14
52	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018, 13, e0192627.	1.1	6
53	Salvage Therapy or Simplification of Salvage Regimens with Dolutegravir plus Ritonavir-Boosted Darunavir Dual Therapy in Highly cART-Experienced Subjects: An Italian Cohort. <i>Antiviral Therapy</i> , 2017, 22, 257-262.	0.6	17
54	FDG PET/CT in Aortic Valve Bioprosthesis Infection. <i>Clinical Nuclear Medicine</i> , 2017, 42, e347-e348.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Comparing imported malaria in adults and children presenting to an Italian teaching hospital: A 10-year retrospective study. <i>Travel Medicine and Infectious Disease</i> , 2017, 17, 56-61.	1.5	7
56	Antiretroviral therapy in geriatric HIV patients: the GEPO cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2879-2886.	1.3	30
57	Time course of cellular HIV-DNA and low-level HIV viremia in HIV/HCV-co-infected patients whose HCV infection had been successfully treated with directly acting antivirals. <i>Medical Microbiology and Immunology</i> , 2017, 206, 419-428.	2.6	11
58	Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 338-342.	0.9	9
59	<i>Vibrio cholerae</i> non-O1, non-O139 bacteraemia associated with pneumonia, Italy 2016. <i>Infection</i> , 2017, 45, 237-240.	2.3	18
60	A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48-weeks observational data. <i>BMC Infectious Diseases</i> , 2017, 17, 658.	1.3	41
61	Impact of monotherapy on HIV-1 reservoir, immune activation, and co-infection with Epstein-Barr virus. <i>PLoS ONE</i> , 2017, 12, e0185128.	1.1	9
62	Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection. <i>Annals of Gastroenterology</i> , 2017, 30, 534-541.	0.4	1
63	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , 2016, 11, e0151703.	1.1	5
64	Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. <i>International Journal of Infectious Diseases</i> , 2016, 49, 151-153.	1.5	6
65	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw846.	2.9	8
66	Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. <i>Infection</i> , 2016, 44, 747-755.	2.3	34
67	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4434.	0.4	2
68	Predictors of immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma: a case report. <i>Infectious Agents and Cancer</i> , 2016, 11, 5.	1.2	9
69	Cytopenias during Treatment of HIV/HCV-Coinfection with Pegylated Interferon and Ribavirin: Safety Analysis of the OPERA Study. <i>Antiviral Therapy</i> , 2015, 20, 39-48.	0.6	2
70	Ageing with HIV: a multidisciplinary review. <i>Infection</i> , 2015, 43, 509-522.	2.3	22
71	Effect of Aging, Glucose Level, and HIV Viral Load on Response to Treatment with Pegylated Interferon Plus Ribavirin in HIV/HCV Co-Infected Women. <i>Journal of Women's Health</i> , 2015, 24, 159-164.	1.5	0
72	Human and entomological surveillance of West Nile fever, dengue and chikungunya in Veneto Region, Italy, 2010-2012. <i>BMC Infectious Diseases</i> , 2014, 14, 60.	1.3	33

#	ARTICLE	IF	CITATIONS
73	Induced first abortion rates before and after <scp>HIV</scp> diagnosis: results of an Italian self-administered questionnaire survey carried out in 585 women living with <scp>HIV</scp>. HIV Medicine, 2013, 14, 31-39.	1.0	13
74	Prevalence of Prolonged Amenorrhea in HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e19-e21.	0.9	6
75	Oral Human Papillomavirus and Human Herpesvirus-8 Infections Among Human Immunodeficiency Virus Type 1-Infected Men and Women in Italy. Sexually Transmitted Diseases, 2012, 39, 894-898.	0.8	22
76	Epstein-Barr Virus load and immune activation in Human Immunodeficiency Virus type 1-infected patients. Journal of Clinical Virology, 2012, 53, 195-200.	1.6	51
77	Surveillance for West Nile, Dengue, and Chikungunya Virus Infections, Veneto Region, Italy, 2010. Emerging Infectious Diseases, 2012, 18, 671-3.	2.0	29
78	Once-a-Day (QD) vs Twice-Daily (BID) Nevirapine as Simplification in PITreated Patients After 2 mos. of BID Induction. Current HIV Research, 2011, 9, 166-173.	0.2	1
79	The societal burden of HIV/AIDS in Northern Italy: An analysis of costs and quality of life. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 449-455.	0.6	19
80	Diagnosis of infected total knee arthroplasty with anti-granulocyte scintigraphy: the importance of a dual-time acquisition protocol. Nuclear Medicine Communications, 2008, 29, 331-335.	0.5	30
81	Antigranulocyte scintigraphy in infected hip prosthesis: the diagnostic importance of delayed 20-24-h imaging and semiquantitative analysis. Nuclear Medicine Communications, 2008, 29, 994-998.	0.5	13
82	Use of Polylactic Acid Implants to Correct Facial Lipoatrophy in Human Immunodeficiency Virus 1-Positive Individuals Receiving Combination Antiretroviral Therapy. Archives of Dermatology, 2006, 142, 329-34.	1.7	40
83	Linezolid in the treatment of brain abscess due to Peptostreptococcus. Scandinavian Journal of Infectious Diseases, 2006, 38, 203-205.	1.5	13
84	Treatments of AIDS-related Kaposi's sarcoma. Critical Reviews in Oncology/Hematology, 2005, 53, 253-265.	2.0	48
85	Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. International Journal of Oncology, 2005, 27, 779-85.	1.4	22
86	Antiretroviral Therapy and the Clinical Evolution of Human Papillomavirus-Associated Genital Lesions in HIV-Positive Women. Clinical Infectious Diseases, 2004, 38, 737-742.	2.9	73
87	Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy. Scandinavian Journal of Infectious Diseases, 2004, 36, 155-157.	1.5	10
88	Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma. Expert Opinion on Investigational Drugs, 2004, 13, 501-513.	1.9	5
89	Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Quality of Life Research, 2004, 13, 243-250.	1.5	35
90	Sepsis and granulomatous hepatitis after bacillus Calmette-Guerin intravesical installation. Journal of Infection, 2004, 48, 363-364.	1.7	16

#	ARTICLE	IF	CITATIONS
91	Multiple cerebral cryptococcomas associated with immune reconstitution in HIV-1 infection. <i>Aids</i> , 2004, 18, 349-351.	1.0	44
92	Evaluation of Adherence to Antiretroviral Therapy in Italian HIV Patients. <i>AIDS Patient Care and STDs</i> , 2003, 17, 33-41.	1.1	25
93	Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART. <i>HIV Clinical Trials</i> , 2003, 4, 99-106.	2.0	38
94	Severe Hepatitis Associated with Oxacillin Therapy. <i>Southern Medical Journal</i> , 2003, 96, 324-325.	0.3	2
95	Synercid plus vancomycin for the Treatment of Severe Methicillin-resistant <i>Staphylococcus aureus</i> and Coagulase-negative <i>Staphylococci</i> Infections: Evaluation of 5 Cases. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 122-126.	1.5	30
96	Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 63-73.	1.0	73
97	Genital Human Papillomavirus Types in Immunocompetent and Immunodepressed Women in Northeast Italy: Prevalence and Cytomorphological Correlations. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 12-20.	0.9	6
98	Indinavir and systemic hypertension. <i>Aids</i> , 2001, 15, 805-807.	1.0	68
99	aspergillosis after lung transplantation. <i>Transplant International</i> , 2000, 13, 183-186.	0.8	0
100	Different Distribution of HIV Type 1 Genetic Variants in European Patients with Distinct Risk Practices. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 299-304.	0.5	20
101	Chemo-Immunotherapy of Advanced Aids-Related Kaposi'S Sarcoma. <i>Tumori</i> , 1999, 85, 54-59.	0.6	7
102	Molecular Profile of Epstein-Barr Virus in Human Immunodeficiency Virus Type 1-Related Lymphadenopathies and Lymphomas. <i>Blood</i> , 1997, 90, 313-322.	0.6	38
103	Molecular Profile of Epstein-Barr Virus in Human Immunodeficiency Virus Type 1-Related Lymphadenopathies and Lymphomas. <i>Blood</i> , 1997, 90, 313-322.	0.6	16